Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 1998

View Archived Issues

Company Profile: Ophidian

FDA approves PathVysion breast cancer detection kit

Abgenix and RCT enter CD45RB antibody collaboration

Cell Genesys and Collateral Therapeutics collaborate on cardiovascular gene therapy

FDA approves Treatment IND for Orphan Medical's Xyrem oral solution

E.U.-wide Muse approval triggers license and milestone payments from Astra

Allelix treatment for dementia enters phase I trials

Compounds for inhibiting matrix metalloproteinases in development at Hoechst Marion Roussel

Antineoplastic cephalomannine derivatives from Xechem with paclitaxel-like activity

EP1 receptor antagonists described by Ono for pain, fever and diuresis

New alpha2-adrenoceptor antagonist beneficial in stress-induced colonic motor dysfunction

Pharmacological profile of dual LTD4/TxA2 receptor antagonist YM-158

Abbott discloses discovery of selective ETA antagonist as potential backup compound to ABT-627

Corvas/Schering-Plough oral anticoagulant alliance extended

FDA clears first and only once-daily treatment for overactive bladder

First evidence that citicoline favorably affects human brain lipid metabolism

Expanded indications, new formulation of Lamictal now available in U.S.

Tobishi's pollen extract improves bladder dysfunction, nonbacterial prostatitis in rats

FDA approves abacavir for treatment of HIV-1 infection

Vesnarinone: adverse and favorable effects in CHF

Pharmacia & Upjohn to copromote Pletal tablets with Otsuka

AxyS and Rhone-Poulenc Rorer enter collaborative agreement

Preliminary analysis of phase II trial indicates efficacy and safety of Topiglan gel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...